This matching program complies with these requirements.

Linda Boyer,

Deputy Commissioner, OCSS.

PARTICIPATING AGENCIES:

The agencies participating in the matching program are OCSS (source agency) and state agencies administering the TANF program (non-Federal agencies).

AUTHORITY FOR CONDUCTING THE MATCHING PROGRAM:

The authority for conducting the matching program is contained in section 453(j)(3) of the Social Security Act (42 U.S.C. 653(j)(3)).

PURPOSE(S):

The purpose of the matching program is to compare name and Social Security Number (SSN) combinations of TANF applicant and recipient records from each participating state agency administering TANF with new hire, quarterly wage, and unemployment insurance information maintained in the OCSS NDNH system of records. Any match results from the comparison are returned to the state TANF agency to help them with establishing or verifying TANF applicants' and recipients' eligibility for assistance, reducing payment errors, and maintaining program integrity, including determining whether duplicate participation exists or if the applicant or recipient resides in another state. The state TANF agencies may also use the NDNH match information to update the recipients' reported participation in work activities and recipients' and their employers' contact information maintained by the state TANF agencies.

CATEGORIES OF INDIVIDUALS:

The categories of individuals involved in the matching program are adult TANF applicants and recipients.

CATEGORIES OF RECORDS:

The categories of records involved in the TANF–NDNH matching program, which include personal identifiers, are new hire, quarterly wage, and unemployment insurance information. For successful comparison, state TANF input files sent to OCSS must be programmed according to TANF–NDNH Record Specifications and must include the individual applicant or recipient's name and SSN. The state TANF agency may use alpha-numeric characters in the Passback Data field of the input file to identify the specific authorized purpose for which the record is being submitted for NDNH matching. They may also use the same State Data Indicator field to indicate whether or not to receive NDNH data that was provided by the state. OCSS will compare the SSNs in the state TANF agency input file to the SSNs in the NDNH and will send the state agency an output file with any available new hire, quarterly wage, and available unemployment insurance information in the NDNH that matched the name and SSNs in the state TANF agency input file records. The NDNH data elements that OCSS will return to the state agency are:

a. New Hire File

- New hire processed date
- Employee name and address
- Employee date and state of hire
- Federal and state employer identification numbers
- Department of Defense code
- Employer name and address
- Transmitter agency code
- Transmitter state code
- Transmitter state or agency name

b. Quarterly Wage File

- Quarterly wage processed date
- Employee name
- Federal and state employer identification numbers
- Department of Defense code
- Employer name and address
- Employee wage amount
- Quarterly wage reporting period
- Transmitter agency code
- Transmitter state code
- Transmitter state or agency name

c. Unemployment Insurance File

- Unemployment insurance processed date
- Claimant name and address
- Claimant benefit amount
- Unemployment insurance reporting period
- Transmitter state code
- Transmitter state or agency name

SYSTEM(S) OF RECORDS:

The NDNH data used in this matching program will be disclosed from the following OCSS system of records, as authorized by routine use 8: *OCSS National Directory of New Hires,* System No. 09–80–0381; 89 FR 25625 (Apr. 11, 2024).

[FR Doc. 2025–10985 Filed 6–17–25; 8:45 am]

BILLING CODE 4184–42–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2025–N–0835]

Modified Risk Tobacco Product Application: Applications for ZYN Products Submitted by Swedish Match U.S.A., Inc.

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; request for comments.

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing an opportunity to provide public comment on modified risk tobacco product applications (MRTPAs) submitted by Swedish Match U.S.A., Inc. for *ZYN* oral pouch products containing nicotine derived from tobacco.

DATES: Electronic or written comments on the applications may be submitted beginning June 18, 2025. FDA will establish a closing date for the comment period as described in section I.

ADDRESSES: You may submit comments as follows:

Electronic Submissions

Submit electronic comments in the following way:

- *Federal eRulemaking Portal: https://www.regulations.gov.* Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on *https://www.regulations.gov.*
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ''Written/Paper Submissions'' and ''Instructions'').

Written/Paper Submissions

Submit written/paper submissions as follows:

- *Mail/Hand Delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ''Instructions.''

Instructions: All submissions received must include the Docket No. FDA–2025–N–0835 for ''Modified Risk

Tobacco Product Applications: Applications for *ZYN oral pouch products containing nicotine derived from tobacco* submitted by Swedish Match U.S.A., Inc.'' Received comments will be placed in the docket and, except for those submitted as ''Confidential Submissions,'' publicly viewable at *https://www.regulations.gov* or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500.

• Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ''THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on *https://www.regulations.gov.* Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ''confidential.'' Any information marked as ''confidential'' will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: *https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.*

Docket: For access to the docket to read the electronic and written/paper comments received, go to *https://www.regulations.gov* and insert the docket number, found in brackets in the heading of this document, into the ''Search'' box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500.

FOR FURTHER INFORMATION CONTACT: Erin Ellis, Office of Science, Center for Tobacco Products, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. G335, Silver Spring, MD 20993–0002, 1–877–287–1373, email: *AskCTP@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION:

I. Background

Section 911 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 387k) addresses the marketing and distribution of modified risk tobacco products (MRTPs). MRTPs are tobacco products that are sold or distributed for use to reduce harm or the risk of tobacco-related disease associated with commercially marketed tobacco products. Section 911(a) of the FD&C Act prohibits the introduction or delivery for introduction into interstate commerce of any MRTP unless an order issued by FDA pursuant to section 911(g) of the FD&C Act is effective with respect to such product.

Section 911(d) of the FD&C Act describes the information that must be included in a MRTPA, which must be filed and evaluated by FDA before an applicant can receive an order from FDA. FDA is required by section 911(e) of the FD&C Act to make a MRTPA available to the public (except for matters in the application that are trade secrets or otherwise confidential commercial information) and to request comments by interested persons on the information contained in the application and on the label, labeling, and advertising accompanying the application. The determination of whether an order is appropriate under section 911 of the FD&C Act is based on the scientific information submitted by the applicant as well as the scientific evidence and other information that is made available to the Agency, including through public comments.

Section 911(g) of the FD&C Act describes the demonstrations applicants must make to obtain an order from FDA under either section 911(g)(1) or (2). The applicant, Swedish Match U.S.A., Inc., is seeking a modified risk granted order under section 911(g)(1) of the FD&C Act.

FDA may issue an order under section 911(g)(1) of the FD&C Act, if FDA has determined that the applicant has demonstrated that the proposed MRTP, as it is actually used by consumers, will:

• Significantly reduce harm and the risk of tobacco-related disease to individual tobacco users; and

• Benefit the health of the population as a whole taking into account both users of tobacco products and persons who do not currently use tobacco products.

Section 911(g)(4) of the FD&C Act describes factors that FDA must take into account in evaluating whether a tobacco product benefits the health of individuals and the population as a whole.

FDA is issuing this notice to inform the public that the MRTPAs for the following products submitted by Swedish Match U.S.A., Inc. have been filed and are being made available for public comment:

- MR0000268.PD1: ZYN Cool Mint 3 mg
- MR0000268.PD2: ZYN Cool Mint 6 mg
- MR0000268.PD3: ZYN Peppermint 3 mg
- MR0000268.PD4: ZYN Peppermint 6 mg
- MR0000268.PD5: ZYN Spearmint 3 mg
- MR0000268.PD6: ZYN Spearmint 6 mg
- MR0000268.PD7: ZYN Wintergreen 3 mg
- MR0000268.PD8: ZYN Wintergreen 6 mg
- MR0000268.PD9: ZYN Citrus 3 mg
- MR0000268.PD10: ZYN Citrus 6 mg
- MR0000268.PD11: ZYN Coffee 3 mg
- MR0000268.PD12: ZYN Coffee 6 mg
- MR0000268.PD13: ZYN Cinnamon 3 mg
- MR0000268.PD14: ZYN Cinnamon 6 mg
- MR0000268.PD15: ZYN Smooth 3 mg [1]
- MR0000268.PD16: ZYN Smooth 6 mg [2]
- MR0000268.PD17: ZYN Chill 3 mg [3]
- MR0000268.PD18: ZYN Chill 6 mg [4]
- MR0000268.PD19: ZYN Menthol 3 mg [5]
- MR0000268.PD20: ZYN Menthol 6 mg.[6]

FDA will post the application documents, including any amendments, to its website for the MRTPAs (see section II) for public comment on a rolling basis as they are redacted in accordance with applicable laws. In this document, FDA is announcing the availability of the first batch of application documents for public comment. FDA intends to establish a closing date for the comment period that is both at least 180 days after the date of this notice and at least 30 days after the final documents from the application are made available for public comment. FDA will announce the closing date at least 30 days in advance. FDA believes that this comment period is appropriate given

[1] Product may also be marketed as ZYN Original 3 mg.

[2] Product may also be marketed as ZYN Original 6 mg.

[3] Product may also be marketed as ZYN Classic 3 mg.

[4] Product may also be marketed as ZYN Classic 6 mg.

[5] Product may also be marketed as ZYN Fresh 3 mg.

[6] Product may also be marketed as ZYN Fresh 6 mg.

the volume and complexity of the applications being posted.

FDA will notify the public about the availability of additional application documents and comment period closing date via the Agency's web page for the MRTPAs (see section II) and by other means of public communication, such as by email to individuals who have signed up to receive email alerts. To receive email alerts, visit FDA's email subscription service management website (*https://www.fda.gov/about-fda/contact-fda/get-email-updates*), provide an email address, scroll down to the ''Tobacco'' heading, select ''Modified Risk Tobacco Product Application Update'', and click ''Submit''. To encourage public participation consistent with section 911(e) of the FD&C Act, FDA is making the redacted MRTPAs that are the subject of this notice available electronically (see section II).

II. Electronic Access

Persons with access to the internet may obtain the document(s) at *https://www.fda.gov/tobacco-products/advertising-and-promotion/swedish-match-usa-inc-modified-risk-tobacco-product-mrtp-applications-zyn-products.*

Dated: June 9, 2025.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2025–10821 Filed 6–17–25; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2024–N–0730]

Cheese Products Deviating From Standard of Identity; Temporary Permit for Market Testing

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or we) is announcing an amendment to the temporary permit issued to Bongards' Creameries to market test pasteurized process cheese deviating from the standard of identity for these cheeses by using extra virgin olive oil as the slice anti-sticking agent. We are also announcing an extension to this permit, which allows Bongards' Creameries to continue to evaluate commercial viability of the product and to collect data on consumer acceptance of the product in support of a petition to amend the standard of identity. We invite other interested parties to participate in the market test.

DATES: The new expiration date of the permit will be either the effective date of a final rule amending the standard of identity of cheese products that may result from the petition or 30 days after denial of the petition.

FOR FURTHER INFORMATION CONTACT: Marjan Morravej, Product Evaluation Labeling Branch, Division of Food Labeling and Standards, Office of Nutrition and Food Labeling, Nutrition Center of Excellence, Human Foods Program, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240–402–2371, *FDAFoodsProgramTMP@fda.hhs.gov,* or Keronica Richardson, Office of Policy, Regulations, and Information, Human Foods Program, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240–402–2378.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of April 28, 2023 (88 FR 26322), we issued a temporary permit to Bongards' Creameries, to market test products deviating from the standards of identity for cheeses and cheese products under 21 CFR 133.167, 133.169, 133.170, 133.171, 133.173, 133.174, 133.175, 133.179, and 133.180. The permit allowed Bongards' Creameries to use extra virgin olive oil as the slice anti-sticking agent in these cheeses and cheese products, which is not permitted under their standards of identity.

On October 14, 2024, Bongards' Creameries requested that its permit be amended to list 21 CFR 133.169 as the applicable standard of identity from which its products may deviate. Such action would remove all other standards of identity from the permit. Accordingly, consistent with 21 CFR 130.17(f), we are amending the temporary permit issued to Bongards' Creameries to provide that it may test market products that deviate from the standard of identity for pasteurized process cheese under 21 CFR 133.169. All other terms and conditions of this permit remain the same.

In addition, we are announcing the extension of this permit in accordance with 21 CFR 130.17(i). On March 18, 2024, Bongards' Creameries submitted a request to extend the temporary permit. On this same date, Bongards' Creameries submitted a citizen petition (Docket No. FDA–2024–P–1570) requesting that we amend multiple standards of identity for cheeses and cheese products. On October 17, 2024, Bongards' Creameries submitted an amended citizen petition (Docket No. FDA–2024–P–1570), requesting that we amend the standard of identity for pasteurized process cheese at 21 CFR 133.169 to include extra virgin olive oil as a slice anti-sticking agent in the manufacture of such food.

We find that it is in the interest of consumers to extend the permit for continued market testing to gain additional information on consumer expectations and acceptance. Therefore, under § 130.17(i), we are extending the temporary permit granted to Bongards' Creameries for temporary marketing of a maximum of 20 million pounds (9.09 million kilograms) of pasteurized process cheese made with olive oil as the slice anti-sticking agent. The new expiration date of the permit will be either the effective date of a final rule on the proposal in the petition or 30 days after denial of the petition. All other conditions and terms of this permit remain the same.

In addition, consistent with 21 CFR 130.17(i), we invite interested persons to participate in the market test under the conditions of Bongards' Creameries' permit. Under 21 CFR 130.17(i), any person who wishes to participate in the extended market test must notify FDA of their intent to participate. The notification must indicate the products to be tested, provide the area of distribution and amount of product to be distributed, and include the labeling that will be used for the test product. We request that a draft label for each test product and each brand of product be submitted. The information panels on the labels of the test products must bear nutrition labeling in accordance with 21 CFR 101.9. Each of the ingredients used in the food must be declared on the label as required by 21 CFR part 101. Interested persons should submit their notifications to the Branch Chief, Product Evaluation Labeling Branch, Division of Food Labeling and Standards, Office of Nutrition and Food Labeling, Nutrition Center of Excellence, Human Foods Program, via *FDAFoodsProgramTMP@fda.hhs.gov.*

Dated: June 13, 2025.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2025–11209 Filed 6–17–25; 8:45 am]

BILLING CODE 4164–01–P